Joinn Laboratories(China)Co - Asset Resilience Ratio
Joinn Laboratories(China)Co (603127) has an Asset Resilience Ratio of 15.05% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Joinn Laboratories(China)Co's Asset Resilience Ratio has changed over time. Check 603127 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Joinn Laboratories(China)Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603127 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.51 Billion | 15.05% |
| Total Liquid Assets | CN¥1.51 Billion | 15.05% |
Asset Resilience Insights
- Good Liquidity Position: Joinn Laboratories(China)Co maintains a healthy 15.05% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Joinn Laboratories(China)Co Industry Peers by Asset Resilience Ratio
Compare Joinn Laboratories(China)Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
Annual Asset Resilience Ratio for Joinn Laboratories(China)Co (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Joinn Laboratories(China)Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 17.75% | CN¥1.72 Billion ≈ $251.44 Million |
CN¥9.68 Billion ≈ $1.42 Billion |
+2.89pp |
| 2024-12-31 | 14.86% | CN¥1.40 Billion ≈ $204.30 Million |
CN¥9.40 Billion ≈ $1.37 Billion |
+11.14pp |
| 2023-12-31 | 3.72% | CN¥373.35 Million ≈ $54.63 Million |
CN¥10.03 Billion ≈ $1.47 Billion |
-0.22pp |
| 2022-12-31 | 3.94% | CN¥408.47 Million ≈ $59.77 Million |
CN¥10.36 Billion ≈ $1.52 Billion |
-4.04pp |
| 2021-12-31 | 7.98% | CN¥680.98 Million ≈ $99.65 Million |
CN¥8.54 Billion ≈ $1.25 Billion |
-3.36pp |
| 2020-12-31 | 11.33% | CN¥238.90 Million ≈ $34.96 Million |
CN¥2.11 Billion ≈ $308.44 Million |
+2.12pp |
| 2019-12-31 | 9.22% | CN¥130.70 Million ≈ $19.13 Million |
CN¥1.42 Billion ≈ $207.47 Million |
+0.21pp |
| 2018-12-31 | 9.01% | CN¥102.85 Million ≈ $15.05 Million |
CN¥1.14 Billion ≈ $167.02 Million |
+8.96pp |
| 2017-12-31 | 0.06% | CN¥519.97K ≈ $76.09K |
CN¥940.87 Million ≈ $137.68 Million |
-- |
About Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics… Read more